Teehan Brendan 4

What Happened

• Brendan Teehan, Chief Commercial Officer of Pacira BioSciences (PCRX), was granted 51,714 restricted stock units (RSUs) on February 11, 2026. The grant is reported as an award/acquisition at $0.00 (no cash purchase).
• These RSUs are a contingent right to receive shares in the future; they do not represent immediately vested shares or an open-market purchase/sale.

Key Details

• Transaction date: 2026-02-11; reported on Form 4 filed 2026-02-13 (timely filing).
• Grant: 51,714 RSUs, acquisition code A, $0.00 per unit (no immediate cash value realized).
• Vesting: RSUs vest in four equal annual installments beginning February 15, 2027 (per filing footnote). Each RSU equals the right to one share upon vesting.
• Shares owned after transaction: not specified in the filing.
• No 10b5-1 plan, tax-withholding sale, or exercise noted — this was a standard equity award.

Context

• RSU grants are compensation/retention awards that convert to common stock only if and when they vest; they are different from open-market purchases or immediate sales and do not by themselves indicate near-term buying or selling by the insider.
• For retail investors, such grants are common for executives and are primarily a form of deferred compensation and retention rather than a direct signal of personal trading intent.